List view / Grid view
9 September 2013 | By Boehringer Ingelheim
Data from two 48 week Phase III studies involving more than 3,000 patients...
9 September 2013 | By
In patients with symptomatic asthma despite moderate-dose maintenance ICS therapy, the addition of tiotropium Respimat® significantly improves lung function and provides sustained bronchodilation over 24 hours.1
9 September 2013 | By Boehringer Ingelheim
TIOSPIR™, with over 17,000 COPD patients included and one of the largest international COPD trials ever conducted...
3 September 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announces new plans to expand body of evidence for Pradaxa®...
2 September 2013 | By Boehringer Ingelheim
Results from TIOSPIR™ will be presented for the first time at the Annual Congress of the European Respiratory Society...
26 August 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announced the upcoming presentation of new data on the novel oral anticoagulant (NOAC) Pradaxa® (dabigatran etexilate) during the ESC Congress 2013...
15 August 2013 | By OgilvyHealthPR London
Data published in The Lancet showed that elderly people with Type 2 Diabetes (T2D) treated for 24 weeks with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, marketed by Boehringer Ingelheim and Eli Lilly and Company, experienced significant reductions in blood glucose levels (HbA1c) compared with those receiving placebo. In addition, the…
15 August 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announced that enrolment of over 950 treatment naïve genotype-1b patients in the pivotal Phase III interferon-free HCVerso™ 1 and 2 trials is complete...
14 August 2013 | By Boehringer Ingelheim
Boehringer Ingelheim grew further in the first half of 2013, despite difficult overall conditions...
1 August 2013 | By Boehringer Ingelheim
Data from the LUX-Lung clinical trial programme...
31 July 2013 | By Boehringer Ingelheim
Boehringer Ingelheim (BI) and Eli Lilly and Company today announced enrollment of the first patient into a cardiovascular and renal outcomes trial for linagliptin (Trajenta®). The CARMELINA1 (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with Type 2 Diabetes mellitus at high vascular risk) trial will investigate the…
26 July 2013 | By Boehringer Ingelheim
"Boehringer Ingelheim welcomes the decision by the CHMP..."
17 July 2013 | By Boehringer Ingelheim
BI and EFSD commit €2.5 million to help accelerate European initiatives...
16 July 2013 | By Boehringer Ingelheim
First approval for afatinib, the frontrunner from Boehringer Ingelheim’s new oncology pipeline...
10 July 2013 | By Boehringer Ingelheim
“We were thrilled by the level of innovation...”
